EcoDrugPlus

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSOGAG00000016421
Gene Symbol: MCL1
4 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOGAG00000003961
Gene Symbol: MET
4 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSOGAG00000008257
Gene Symbol: MPL
4 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSOGAG00000033928
Gene Symbol: MLST8
2 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSOGAG00000004589
Gene Symbol: NQO1
2 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nadph Oxidase 4

Ensembl ID : ENSOGAG00000012261
Gene Symbol: NOX4
2 Cross references
151 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSOGAG00000034393
Gene Symbol: NFE2L2
2 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSOGAG00000030638
Gene Symbol: NPC1L1
2 Cross references
189 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOGAG00000026527
Gene Symbol: PIM1
4 Cross references
244 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOGAG00000009613
Gene Symbol: PIM2
2 Cross references
115 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSOGAG00000029487
Gene Symbol: PIM3
4 Cross references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rar Related Orphan Receptor C

Ensembl ID : ENSOGAG00000024385
Gene Symbol: RORC
4 Cross references
382 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).